Topic:

M&A

Latest Headlines

Latest Headlines

Unilife attracts potential bidder, hires Morgan Stanley to review strategic alternatives

Unilife gained on acquisition speculation after a Sept. 2 disclosure that it has received interest from a potential acquirer and will start a process to review its options. The micro-cap has seen its share price tick up, but its valuation remains at only about $175 million.

UCB hands off U.S. generics business to Lannett for $1.23B

Belgium's UCB has had a tough time unloading its U.S. generic drug business, calling off a sale last year amid regulatory pushback over one of the unit's products. Now the company is closing one chapter and moving on to the next, selling the business to Lannett for $1.23 billion to lighten its load and refocus on high-growth areas.  

Chinese drugmaker trades $200M for CDMO Cytovance

China's Shenzhen Hepalink Pharmaceutical signed a deal to acquire contract drugmaker Cytovance Biologics for $205.7 million in cash, buying into the U.S.'s burgeoning market for large-molecule treatments.

Valeant to buy microsurgery tools company Synergetics for up to $190M

Mega acquirer Valeant Pharmaceuticals is building on its Bausch + Lomb ophthalmic buy from two years ago with a purchase of ophthalmic and neurology microsurgery tool Synergetics for up to about $190M. Investors in the micro-cap saw its share price climb by about 50% on the news.

Report: Baxalta's $2B plot to buy Ariad broke down over price

Last week's buzz that Baxalta, angling to shake off some unwanted buyout attention from Shire, had set sights on Ariad Pharmaceuticals sent the latter company's shares soaring. But negotiations between the two have since fallen apart, according to Bloomberg.

Medtronic to buy cerebral aneurysm stealth startup Medina for $150M+

In its eighth disclosed acquisition this year, Medtronic will purchase vascular aneurysm player Medina Medical for $150 million plus additional undisclosed milestone payments. The stealthy startup already has a CE mark for its embolization device to treat cerebral aneurysm.

Can Baxalta hold off Shire with its own bid for Ariad?

Baxalta may not want to be snatched up at its young age, as it told Irish suitor Shire early this month. But that doesn't mean it doesn't want to land some deals itself--and Ariad Pharmaceuticals may be on its radar.

Amicus bags PhIII rare disease drug in $847M Scioderm buyout

Amicus Therapeutics has stepped in to snap up the late-stage rare disease biotech Scioderm, beefing up its orphan drug pipeline in exchange for $229 million in stock and cash along with a promise of up to $618 million more for meeting a slate of milestones.

Buzz: Ariad soars on reports that Baxalta has come calling about a buyout

Shire has been quiet since making its unwelcomed $30 billion bid to acquire Baxalta public earlier this month. But Baxalta evidently isn't waiting for the next step to play out in that dance. Bloomberg is reporting this afternoon that Baxalta is hunting for an acquisition around the $2 billion mark that would add to its hematology pipeline.

Abbott's next big acquisition: Wall Street wonders, if not St. Jude, then who?

Wall Street is taking Abbott's claim that it is not interested in St. Jude Medical at face value, paving the way for speculation about who the drug and devicemaker will buy instead as it seeks to deploy plentiful cash and bulk up in med tech following a wave of industry M&A.